BIRC2: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of BIRC2. The page also collects GeneMedi's different modalities and formats products for BIRC2 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the BIRC2 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Introcelluar Protein.
The protein encoded by this gene is a member of a family of proteins that inhibits apoptosis by binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2, probably by interfering with activation of ICE-like proteases. This encoded protein inhibits apoptosis induced by serum deprivation and menadione, a potent inducer of free radicals. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2012]
Target ID | GM-T84780 |
Target Name | BIRC2 |
Gene ID | 329,11797,60371,702592,479464,101101663,539314,100061273 |
Gene Symbol and Synonyms | API1,Api2,BIRC2,Birc3,c-IAP1,C330006D17Rik,cIAP1,cIAP2,Hiap-2,HIAP1,HIAP2,IAP1,IAP2,mcIAP1,MIAP1,MIAP2,MIHB,MIHC,rIAP1,RNF48 |
Uniprot Accession | Q13490 |
Uniprot Entry Name | BIRC2_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | Therapeutics Target |
Disease | Cancer |
Gene Ensembl | ENSG00000110330 |
Target Classification | Tumor-associated antigen (TAA) |
Pre-made anti-BIRC2 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-BIRC2 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-BIRC2 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Antibody Name | Species | Format | Classified by tag | Detail |
Anti-BIRC2 monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | Therapeutics Target antibody | Detail |
Recombinant multi-species BIRC2/ API1/ HIAP2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BIRC2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Products Name | Species | Expression Platform | Detail |
BIRC2 protein | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Detail |